drugset / Trial / NCT03781960
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the effectiveness of the combination of nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this study are to learn about the side effects that this combination of drugs may cause and to learn more about how these drugs work by studying blood and tissue.
Timeline
- Start
- 2019-07-31
- Primary completion
- 2022-04-29
- Completion
- 2022-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |